Company Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Country | Denmark |
| Founded | 1923 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64,319 |
| CEO | Lars Fruergaard Jorgensen |
Contact Details
Address: Novo Alle Dk 2880 Bagsvaerd Denmark, G7 00000 Denmark | |
| Phone | 4544448888 |
| Website | novonordisk.com |
Stock Details
| Ticker Symbol | NVO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000353278 |
| CUSIP Number | 670100205 |
| ISIN Number | US6701002056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lars Fruergaard Jorgensen | President, Chief Executive Officer and Member of Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer and Member of the Management Board |
| Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality and IT and Member of the Management Board |
| Camilla Sylvest | Executive Vice President of Commercial Strategy and Corporate Affairs and Member of the Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Development and Member of the Management Board |
| Dr. Marcus Schindler Ph.D. | Executive Vice President of Research and Early Development, Chief Scientific Officer & Member of the Management Board |
| Maziar Mike Doustdar | Executive Vice President of International Operations and Member of the Management Board |
| Douglas J. Langa | Executive Vice President of North America Operations and Member of Management Board |
| Ludovic Helfgott | Executive Vice President, Head of Rare Disease and Member of Management Board |
| Tania Sabroe | Executive Vice President of Global People and Organisation and Member of Management Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 6-K | Report of foreign issuer |
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 6-K | Report of foreign issuer |
| Mar 25, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Mar 18, 2024 | 6-K | Report of foreign issuer |